Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
3.4300+0.0400 (+1.18%)
At close: 11:09AM EDT
Currency in CAD

Valuation measures4

Market cap (intra-day) 120.76M
Enterprise value 84.74M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.52
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.88

Trading information

Stock price history

Beta (5Y monthly) 1.18
52-week change 3-55.34%
S&P500 52-week change 322.23%
52-week high 38.4600
52-week low 33.2500
50-day moving average 33.7015
200-day moving average 34.9915

Share statistics

Avg vol (3-month) 318.4k
Avg vol (10-day) 310.71k
Shares outstanding 535.62M
Implied shares outstanding 635.62M
Float 829.89M
% held by insiders 16.93%
% held by institutions 111.92%
Shares short (28 Jun 2024) 426.87k
Short ratio (28 Jun 2024) 41.91
Short % of float (28 Jun 2024) 40.12%
Short % of shares outstanding (28 Jun 2024) 40.08%
Shares short (prior month 31 May 2024) 42.56k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-75.51%
Return on equity (ttm)-267.25%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -30.89M
Net income avi to common (ttm)-30.37M
Diluted EPS (ttm)-1.6400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)35.91M
Total cash per share (mrq)1.01
Total debt (mrq)9.56M
Total debt/equity (mrq)52.78%
Current ratio (mrq)1.95
Book value per share (mrq)0.55

Cash flow statement

Operating cash flow (ttm)-22.24M
Levered free cash flow (ttm)-11.28M